271 related articles for article (PubMed ID: 31408414)
1. T-Cell Receptor Gene Therapy for Human Papillomavirus-Associated Epithelial Cancers: A First-in-Human, Phase I/II Study.
Doran SL; Stevanović S; Adhikary S; Gartner JJ; Jia L; Kwong MLM; Faquin WC; Hewitt SM; Sherry RM; Yang JC; Rosenberg SA; Hinrichs CS
J Clin Oncol; 2019 Oct; 37(30):2759-2768. PubMed ID: 31408414
[TBL] [Abstract][Full Text] [Related]
2. TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers.
Nagarsheth NB; Norberg SM; Sinkoe AL; Adhikary S; Meyer TJ; Lack JB; Warner AC; Schweitzer C; Doran SL; Korrapati S; Stevanović S; Trimble CL; Kanakry JA; Bagheri MH; Ferraro E; Astrow SH; Bot A; Faquin WC; Stroncek D; Gkitsas N; Highfill S; Hinrichs CS
Nat Med; 2021 Mar; 27(3):419-425. PubMed ID: 33558725
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus 16 (HPV16) and HPV52 E6-specific immunity in HIV-infected adults on combination antiretroviral therapy.
Leng CY; Low HC; Chua LL; Chong ML; Sulaiman H; Azwa I; Roberts JM; Kamarulzaman A; Rajasuriar R; Woo YL
HIV Med; 2017 May; 18(5):321-331. PubMed ID: 27649852
[TBL] [Abstract][Full Text] [Related]
4. A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus-associated Epithelial Cancers.
Stevanović S; Helman SR; Wunderlich JR; Langhan MM; Doran SL; Kwong MLM; Somerville RPT; Klebanoff CA; Kammula US; Sherry RM; Yang JC; Rosenberg SA; Hinrichs CS
Clin Cancer Res; 2019 Mar; 25(5):1486-1493. PubMed ID: 30518633
[TBL] [Abstract][Full Text] [Related]
5. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells.
Stevanović S; Draper LM; Langhan MM; Campbell TE; Kwong ML; Wunderlich JR; Dudley ME; Yang JC; Sherry RM; Kammula US; Restifo NP; Rosenberg SA; Hinrichs CS
J Clin Oncol; 2015 May; 33(14):1543-50. PubMed ID: 25823737
[TBL] [Abstract][Full Text] [Related]
6. Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias.
Carella AM; Lerma E; Dejana A; Corsetti MT; Celesti L; Bruni R; Benvenuto F; Figari O; Parodi C; Carlier P; Florio G; Lercari G; Valbonesi M; Casarino L; De Stefano F; Geniram A; Venturino M; Tedeschi L; Palmieri G; Piaggio G; Podestà M; Frassoni F; Van Lint MT; Marmont AM; Bacigalupo A
Haematologica; 1998 Oct; 83(10):904-9. PubMed ID: 9830799
[TBL] [Abstract][Full Text] [Related]
7. Isolation and Characterization of an HLA-DRB1*04-Restricted HPV16-E7 T Cell Receptor for Cancer Immunotherapy.
Mercier-Letondal P; Marton C; Deschamps M; Ferrand C; Vauchy C; Chenut C; Baguet A; Adotévi O; Borg C; Galaine J; Godet Y
Hum Gene Ther; 2018 Oct; 29(10):1202-1212. PubMed ID: 30136612
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer.
Aggarwal C; Cohen RB; Morrow MP; Kraynyak KA; Sylvester AJ; Knoblock DM; Bauml JM; Weinstein GS; Lin A; Boyer J; Sakata L; Tan S; Anton A; Dickerson K; Mangrolia D; Vang R; Dallas M; Oyola S; Duff S; Esser M; Kumar R; Weiner D; Csiki I; Bagarazzi ML
Clin Cancer Res; 2019 Jan; 25(1):110-124. PubMed ID: 30242022
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus 16 E6-specific CD45RA+ CCR7+ high avidity CD8+ T cells fail to control tumor growth despite interferon-gamma production in patients with cervical cancer.
Zehbe I; Kaufmann AM; Schmidt M; Hohn H; Maeurer MJ
J Immunother; 2007; 30(5):523-32. PubMed ID: 17589293
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.
Lu YC; Parker LL; Lu T; Zheng Z; Toomey MA; White DE; Yao X; Li YF; Robbins PF; Feldman SA; van der Bruggen P; Klebanoff CA; Goff SL; Sherry RM; Kammula US; Yang JC; Rosenberg SA
J Clin Oncol; 2017 Oct; 35(29):3322-3329. PubMed ID: 28809608
[TBL] [Abstract][Full Text] [Related]
11. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters.
Schwaab T; Heaney JA; Schned AR; Harris RD; Cole BF; Noelle RJ; Phillips DM; Stempkowski L; Ernstoff MS
J Urol; 2000 Apr; 163(4):1322-7. PubMed ID: 10737537
[TBL] [Abstract][Full Text] [Related]
12. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7.
Nonn M; Schinz M; Zumbach K; Pawlita M; Schneider A; Dürst M; Kaufmann AM
J Cancer Res Clin Oncol; 2003 Sep; 129(9):511-20. PubMed ID: 12905010
[TBL] [Abstract][Full Text] [Related]
14. Identification of an HLA-A24-restricted cytotoxic T lymphocyte epitope from human papillomavirus type-16 E6: the combined effects of bortezomib and interferon-gamma on the presentation of a cryptic epitope.
Morishima S; Akatsuka Y; Nawa A; Kondo E; Kiyono T; Torikai H; Nakanishi T; Ito Y; Tsujimura K; Iwata K; Ito K; Kodera Y; Morishima Y; Kuzushima K; Takahashi T
Int J Cancer; 2007 Feb; 120(3):594-604. PubMed ID: 17096336
[TBL] [Abstract][Full Text] [Related]
15. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
16. Identification of HLA-DR1- and HLA-DR15-restricted human papillomavirus type 16 (HPV16) and HPV18 E6 epitopes recognized by CD4+ T cells from healthy young women.
Gallagher KME; Man S
J Gen Virol; 2007 May; 88(Pt 5):1470-1478. PubMed ID: 17412975
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus type 33 E7 peptides presented by HLA-DR*0402 to tumor-infiltrating T cells in cervical cancer.
Höhn H; Pilch H; Günzel S; Neukirch C; Freitag K; Necker A; Maeurer MJ
J Virol; 2000 Jul; 74(14):6632-6. PubMed ID: 10864677
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus type 16 E7 peptide-directed CD8+ T cells from patients with cervical cancer are cross-reactive with the coronavirus NS2 protein.
Nilges K; Höhn H; Pilch H; Neukirch C; Freitag K; Talbot PJ; Maeurer MJ
J Virol; 2003 May; 77(9):5464-74. PubMed ID: 12692247
[TBL] [Abstract][Full Text] [Related]
19. Human Papillomavirus T-Cell Cross-reactivity in Cervical Cancer: Implications for Immunotherapy Clinical Trial Design.
Helman SR; Stevanovic S; Campbell TE; Kwong MLM; Doran SL; Faquin WC; Hinrichs CS
JAMA Netw Open; 2018 Jul; 1(3):e180706. PubMed ID: 30646017
[TBL] [Abstract][Full Text] [Related]
20. CD8
Masterson L; Lechner M; Loewenbein S; Mohammed H; Davies-Husband C; Fenton T; Sudhoff H; Jani P; Goon P; Sterling J
Eur J Cancer; 2016 Nov; 67():141-151. PubMed ID: 27669501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]